effects [qlco]
Low dose [qnco]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
glucose homeostasis [phsf]
Marker [clna]
CARDIOVASCULAR [bdsy]
Risk [qlco]
Women [popg]
Background [cnce]
Low dose [qnco]
Hormone replacement therapy [topp]
Interest [menp]
treatment [ftcn]
postmenopausal symptoms [dsyn]
Diabetes [dsyn]
Concerns [idcn]
Increased [qnco]
Risk [qlco]
coronary heart disease [dsyn]
Stroke [dsyn]
Conventional [qlco]
Hormone replacement therapy [topp]
Containing [ftcn]
Conjugated oestrogens [horm, phsu, strd]
Equine [mamm]
CEES [orch]
medroxyprogesterone acetate [horm, phsu, strd]
objectives [inpr]
Assessed [acty]
effects [qlco]
glucose homeostasis [phsf]
cardiovascular risk factor [dsyn]
Continuous [idcn]
Oral [spco]
mg% [qnco]
Norethisterone [horm, phsu, strd]
mg% [qnco]
postmenopausal [tmco]
Women [popg]
Design [acty]
DOUBLE BLIND [resa]
randomized controlled trial [inpr, resa]
placebo [topp]
assessments [hlca]
Clamp [medd]
cardiovascular risk factor [dsyn]
Assessed [acty]
treatment [ftcn]
Result [ftcn]
twenty [orch, phsu]
Eight [qnco]
Women [popg]
COMPLETED [qlco]
Study [mnob]
Hormone replacement therapy [topp]
Decreased [qnco]
Fasting [fndg]
Glucose [bacs, carb, phsu]
Compared [acty]
placebo [topp]
Hormone replacement therapy [topp]
placebo [topp]
Confidence Interval [qnco]
Total Cholesterol [lbpr]
Confidence Interval [qnco]
Effect [qlco]
Seen [qlco]
Metabolic Clearance Rate [clna]
Glucose [bacs, carb, phsu]
Glycated haemoglobin [aapp, bacs]
Triglycerides [bacs, lipd]
High Density Lipoprotein Cholesterol [bacs, lipd]
C-reactive protein [aapp, imft]
Conclusions [idcn]
Women [popg]
Low dose [qnco]
Hormone replacement therapy [topp]
Decreased [qnco]
Fasting [fndg]
Glucose [bacs, carb, phsu]
Total Cholesterol [lbpr]
adverse effects [ftcn]
Glucose Clearance [lbpr]
Triglycerides [bacs, lipd]
Cholesterol [bacs, strd]
C-reactive protein [aapp, imft]
Reported [inpr]
Conventional [qlco]
Hormone replacement therapy [topp]
